D-Cateslytin: a new antifungal agent for the treatment of oral Candida albicans associated infections

• DOI: 10.1038/s41598-018-27417-x
• Publication Date: 2018-06-12T09:14:47Z
• Authors: Pauline Dartevelle; Claire Ehlinger; Abdurraouf Zaet; Christian Boehler; Morgane Rabineau; Benoit Westermann; Jean-Marc Strub; Sarah Cianferani; Youssef Haïkel; Marie-Hélène Metz...; Céline Marban
• Keywords: CTL*; Nystatin

Abstract The excessive use of antifungal agents, compounded by the shortage new drugs being introduced into market, is causing accumulation multi-resistance phenotypes in many fungal strains. Consequently, alternative molecules to conventional agents are urgently needed prevent emergence resistance. In this context, Cateslytin (Ctl), a natural peptide derived from processing Chromogranin A, has already been described as an effective antimicrobial agent against several pathogens including Candida albicans . present study, we compared activity two conformations Ctl, L-Ctl and D-Ctl Our results show that both were potent safe agents. However, contrast L-Ctl, was not degraded proteases secreted also stable saliva. Using video microscopy, demonstrated can rapidly enter C. , but unable spread within yeast colony unless mother cell daughter during cellular division. Besides, revealed could be synergized voriconazole, reference treatment related infections. conclusion, considered effective, used alone or combination therapy with voriconazole treat diseases oral candidosis.